🚀 VC round data is live in beta, check it out!
Fennec Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fennec Pharmaceuticals and similar public comparables like Nuvectis Pharma, Camp4 Therapeutics, OmniAb, Sol-Gel Technologies and more.
Fennec Pharmaceuticals Overview
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Founded
1998
HQ
Employees
32
Website
Sectors
Financials (LTM)
EV
$199M
Fennec Pharmaceuticals Financials
Fennec Pharmaceuticals reported last 12-month revenue of $52M and EBITDA of $3M.
In the same LTM period, Fennec Pharmaceuticals generated $48M in gross profit, $3M in EBITDA, and had net loss of ($6M).
Revenue (LTM)
Fennec Pharmaceuticals P&L
In the most recent fiscal year, Fennec Pharmaceuticals reported revenue of $45M and EBITDA of ($900K).
Fennec Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $52M | XXX | $45M | XXX | XXX | XXX |
| Gross Profit | $48M | XXX | $41M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | $3M | XXX | ($900K) | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | (2%) | XXX | XXX | XXX |
| EBIT Margin | (7%) | XXX | (14%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($10M) | XXX | XXX | XXX |
| Net Margin | (11%) | XXX | (22%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Fennec Pharmaceuticals Stock Performance
Fennec Pharmaceuticals has current market cap of $236M, and enterprise value of $199M.
Market Cap Evolution
Fennec Pharmaceuticals' stock price is $6.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $199M | $236M | 10.8% | XXX | XXX | XXX | $-0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFennec Pharmaceuticals Valuation Multiples
Fennec Pharmaceuticals trades at 3.8x EV/Revenue multiple, and 78.7x EV/EBITDA.
EV / Revenue (LTM)
Fennec Pharmaceuticals Financial Valuation Multiples
As of April 19, 2026, Fennec Pharmaceuticals has market cap of $236M and EV of $199M.
Equity research analysts estimate Fennec Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fennec Pharmaceuticals has a P/E ratio of (40.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $236M | XXX | $236M | XXX | XXX | XXX |
| EV (current) | $199M | XXX | $199M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 78.7x | XXX | (221.5x) | XXX | XXX | XXX |
| EV/EBIT | (57.8x) | XXX | (31.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | 4.9x | XXX | XXX | XXX |
| P/E | (40.3x) | XXX | (24.2x) | XXX | XXX | XXX |
| EV/FCF | (38.0x) | XXX | (16.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fennec Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Fennec Pharmaceuticals Margins & Growth Rates
Fennec Pharmaceuticals' revenue in the last 12 month grew by 53%.
Fennec Pharmaceuticals' revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.5M for the same period.
Fennec Pharmaceuticals' rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fennec Pharmaceuticals' rule of X is 153% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Fennec Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 53% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Growth | 484% | XXX | (1289%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 70% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 153% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 40% | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 57% | XXX | 64% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 106% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Fennec Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fennec Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvectis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Sol-Gel Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Saniona | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fennec Pharmaceuticals M&A Activity
Fennec Pharmaceuticals acquired XXX companies to date.
Last acquisition by Fennec Pharmaceuticals was on XXXXXXXX, XXXXX. Fennec Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Fennec Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFennec Pharmaceuticals Investment Activity
Fennec Pharmaceuticals invested in XXX companies to date.
Fennec Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Fennec Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Fennec Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fennec Pharmaceuticals
| When was Fennec Pharmaceuticals founded? | Fennec Pharmaceuticals was founded in 1998. |
| Where is Fennec Pharmaceuticals headquartered? | Fennec Pharmaceuticals is headquartered in United States. |
| How many employees does Fennec Pharmaceuticals have? | As of today, Fennec Pharmaceuticals has over 32 employees. |
| Who is the CEO of Fennec Pharmaceuticals? | Fennec Pharmaceuticals' CEO is Jeffrey S. Hackman. |
| Is Fennec Pharmaceuticals publicly listed? | Yes, Fennec Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Fennec Pharmaceuticals? | Fennec Pharmaceuticals trades under FENC ticker. |
| When did Fennec Pharmaceuticals go public? | Fennec Pharmaceuticals went public in 2002. |
| Who are competitors of Fennec Pharmaceuticals? | Fennec Pharmaceuticals main competitors are Nuvectis Pharma, Camp4 Therapeutics, OmniAb, Sol-Gel Technologies. |
| What is the current market cap of Fennec Pharmaceuticals? | Fennec Pharmaceuticals' current market cap is $236M. |
| What is the current revenue of Fennec Pharmaceuticals? | Fennec Pharmaceuticals' last 12 months revenue is $52M. |
| What is the current revenue growth of Fennec Pharmaceuticals? | Fennec Pharmaceuticals revenue growth (NTM/LTM) is 53%. |
| What is the current EV/Revenue multiple of Fennec Pharmaceuticals? | Current revenue multiple of Fennec Pharmaceuticals is 3.8x. |
| Is Fennec Pharmaceuticals profitable? | Yes, Fennec Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fennec Pharmaceuticals? | Fennec Pharmaceuticals' last 12 months EBITDA is $3M. |
| What is Fennec Pharmaceuticals' EBITDA margin? | Fennec Pharmaceuticals' last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Fennec Pharmaceuticals? | Current EBITDA multiple of Fennec Pharmaceuticals is 78.7x. |
| What is the current FCF of Fennec Pharmaceuticals? | Fennec Pharmaceuticals' last 12 months FCF is ($5M). |
| What is Fennec Pharmaceuticals' FCF margin? | Fennec Pharmaceuticals' last 12 months FCF margin is (10%). |
| What is the current EV/FCF multiple of Fennec Pharmaceuticals? | Current FCF multiple of Fennec Pharmaceuticals is (38.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.